These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
362 related articles for article (PubMed ID: 18946171)
1. Metabolic syndrome is strongly associated with chronic subclinical inflammation in patients achieving optimal low-density lipoprotein-cholesterol levels in secondary prevention of cardiovascular disease. Matsuo Y; Hashizume T; Shioji S; Akasaka T Circ J; 2008 Dec; 72(12):2046-50. PubMed ID: 18946171 [TBL] [Abstract][Full Text] [Related]
2. Obesity, ultrasound indexes of fat depots and lipid goal attainment in patients with high and very high cardiovascular risk: A novel approach towards better risk reduction. Haberka M; Okopień B; Gąsior Z Nutr Metab Cardiovasc Dis; 2016 Feb; 26(2):123-33. PubMed ID: 26830392 [TBL] [Abstract][Full Text] [Related]
3. Statins in cardiometabolic disease: what makes pitavastatin different? Ginsberg H Cardiovasc Diabetol; 2013; 12 Suppl 1(Suppl 1):S1. PubMed ID: 23819727 [TBL] [Abstract][Full Text] [Related]
4. Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome. Ferdinand KC J Cardiometab Syndr; 2006; 1(2):133-40. PubMed ID: 17679832 [TBL] [Abstract][Full Text] [Related]
9. Association of Plasma Pentraxin-3 Level with Lipid Levels and Cardiovascular Risk Factors in People with No History of Lipid-Lowering Medication: the Dong-gu Study. Lee R; Ahn HR; Shin MH; Kim HN; Lee YH; Choi SW; Kweon SS J Atheroscler Thromb; 2019 Aug; 26(8):738-745. PubMed ID: 30674758 [TBL] [Abstract][Full Text] [Related]
10. Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. Bulcão C; Ribeiro-Filho FF; Sañudo A; Roberta Ferreira SG Am J Cardiovasc Drugs; 2007; 7(3):219-24. PubMed ID: 17610348 [TBL] [Abstract][Full Text] [Related]
11. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White JA; Tershakovec AM; Blazing MA; Braunwald E Circulation; 2015 Sep; 132(13):1224-33. PubMed ID: 26330412 [TBL] [Abstract][Full Text] [Related]
12. Frequency of Attainment of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Goals in Cardiovascular Clinical Practice (from the National Cardiovascular Data Registry PINNACLE Registry). Spinler SA; Cziraky MJ; Willey VJ; Tang F; Maddox TM; Thomas T; Dueñas GG; Virani SS; Am J Cardiol; 2015 Aug; 116(4):547-53. PubMed ID: 26089010 [TBL] [Abstract][Full Text] [Related]
13. Association of age and sex with cardiovascular risk factors and insulin sensitivity in overweight children and adolescents. Koenigsberg J; Boyd GS; Gidding SS; Hassink SG; Falkner B J Cardiometab Syndr; 2006; 1(4):253-8. PubMed ID: 17679813 [TBL] [Abstract][Full Text] [Related]
14. Cholesterol goal attainment in hypertensive patients: the impact of metabolic syndrome components. Rodrigues CJ; Ribeiro HF; Ribeiro AB; Zanella MT; Batista MC Metab Syndr Relat Disord; 2012 Jun; 10(3):195-201. PubMed ID: 22313142 [TBL] [Abstract][Full Text] [Related]
15. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum. Ascaso J; Gonzalez Santos P; Hernandez Mijares A; Mangas Rojas A; Masana L; Millan J; Pallardo LF; Pedro-Botet J; Perez Jimenez F; Pintó X; Plaza I; Rubiés J; Zúñiga M Am J Cardiovasc Drugs; 2007; 7(1):39-58. PubMed ID: 17355165 [TBL] [Abstract][Full Text] [Related]
16. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls--the role of inflammation. Tam LS; Tomlinson B; Chu TT; Li M; Leung YY; Kwok LW; Li TK; Yu T; Zhu YE; Wong KC; Kun EW; Li EK Rheumatology (Oxford); 2008 May; 47(5):718-23. PubMed ID: 18400833 [TBL] [Abstract][Full Text] [Related]
17. Roles of Achieved Levels of Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein on Cardiovascular Outcome in Statin Therapy. Hyun MH; Lee Y; Choi BG; Na JO; Choi CU; Kim JW; Kim EJ; Rha SW; Park CG; Lee E; Seo HS Cardiovasc Ther; 2019; 2019():3824823. PubMed ID: 31885691 [TBL] [Abstract][Full Text] [Related]
18. Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women. Athyros VG; Ganotakis E; Kolovou GD; Nicolaou V; Achimastos A; Bilianou E; Alexandrides T; Karagiannis A; Paletas K; Liberopoulos EN; Tziomalos K; Petridis D; Kakafika A; Elisaf MS; Mikhailidis DP; Curr Vasc Pharmacol; 2011 Nov; 9(6):647-57. PubMed ID: 21476961 [TBL] [Abstract][Full Text] [Related]
19. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome. Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516 [TBL] [Abstract][Full Text] [Related]
20. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study. Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]